Sign In
Last checked at 
20 Oct 2025 17:54
PDMR Dealing
Oxford, UK - 20 October 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Kyriacos Mitrophanous, Chief Innovation Officer of the Company, exercised 26,210 LTIP options at nil exercise price on 20 October 2025 and disposed of 26,210 shares at an average price of £5.758376 per share on 20 October 2025.
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Kyriacos Mitrophanous | ||||
2. | Reason for the notification | |||||
a) | Position/status | Person Discharging Managerial Responsibility | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Full name of the entity | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Date of the transaction | 2025-10-20 | ||||
b) | Description of the financial instrument | Options over Ordinary Shares of 50 pence each
| ||||
c) | Identification code | ISIN: GB00BDFBVT43 | ||||
d) | Nature of the transaction | Exercise of LTIP Options at nil exercise price | ||||
e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
f) | Currency | GBP - British pound | ||||
g) | Price(s) and volumes(s)
|
| ||||
h) | Aggregated information - Aggregate volume - Price - Aggregated total |
26,210 £0.00 £0.00 | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Kyriacos Mitrophanous | ||||
2. | Reason for the notification | |||||
a) | Position/status | Person Discharging Managerial Responsibility | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Date of the transaction | 2025-10-20 | ||||
b) | Description of the financial instrument | Ordinary Shares of 50 pence each
| ||||
c) | Identification code | ISIN: GB00BDFBVT43 | ||||
d) | Nature of transaction | Sale of shares | ||||
e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
f) | Currency | GBP - British pound | ||||
g) | Price(s) and volumes(s) |
| ||||
h) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
26,210
£5.758376
£150,927.03 | ||||
-Ends-
Enquiries:
OXB:
Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Follow the stocks
